A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see The explainable aging clock regulators might actually like The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause Galapagos quits cell therapy. Europe’s CGT reckoning begins. The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’? Dermatology’s next play: bispecifics that shut down OX40L and TNF Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030? The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencer Dermatology’s next play: bispecifics that shut down OX40L and TNF Texas Ban on Lab-Grown Meat Triggers Policy and Legal Showdowns Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide Revolutionizing Dairy: How Biotech Companies are Producing Milk Without Cows More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’? Orna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine Development Novo Holdings Leads $100 Million Series C Financing for Asceneuron New Study Highlights the Impact of Early-Life Tobacco Exposure on Accelerated Aging €132M for a Dutch Rare-Disease Upstart: Is Europe Quietly Becoming the New Neurology Capital? From Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging Breakthrough Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market Beijing’s Biotech Blitz Is Outpacing America. Washington Needs a War Plan. A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide Breaking the Bias: How Precision Medicine Can Overcome Ancestral Disparities The Billionaire Longevity Experiment: A Cruise Ship Promises to Extend Life—For a Price Tropic Unveils Gene-Edited Non-Browning Bananas to Reduce Food Waste AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal How AI is Revolutionizing Antibiotic Discovery to Combat Drug-Resistant Bacteria Michigan-Based Biotech Startup CircNova Secures $3.3M Seed Funding to Advance AI-Driven Circular RNA Therapies Illumina’s Market Struggles Deepen as U.S.-China Tensions Escalate Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery Merck KGaA in Talks to Acquire U.S. Biotech Firm SpringWorks, Valued at $4 Billion Light-Based Microcapillary Monitoring Expands Precision in Biotechnology STORIES WE THINK YOU MIGHT LIKE Draupnir Bio Raises €12 Million to Advance Oral Protein Degraders Targeting Extracellular Proteins Novo Holdings Leads $100 Million Series C Financing for Asceneuron German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies Myricx Bio’s NMTi-ADCs Achieve Tumor Regression in Preclinical Trials Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion Brisbane Biotech Gelomics Raises $2.2 Million in Pre-Seed Funding German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies Myricx Bio’s NMTi-ADCs Achieve Tumor Regression in Preclinical Trials Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion Brisbane Biotech Gelomics Raises $2.2 Million in Pre-Seed Funding Alumis IPO Priced at $16, Targets $210M Funding MOST POPULAR Beijing’s Biotech Blitz Is Outpacing America. Washington Needs a War Plan. Gene Editing for Everyone: CRISPRware and the Open-Source Biotech Revolution Texas Ban on Lab-Grown Meat Triggers Policy and Legal Showdowns From Early Detection to Tumor “Education”: Syantra’s Bold Bet on cfRNA in Cancer Tech €132M for a Dutch Rare-Disease Upstart: Is Europe Quietly Becoming the New Neurology Capital? From Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging Breakthrough Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market EU’s €12.5M Bet on Oncomatryx and Antibody-Drug Conjugates (ADCs) A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle Aging Science The explainable aging clock regulators might actually like Impact of Space Travel on Immune Function and Potential Countermeasures Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In Epigenetic Stability Linked to Lifespan in Mammals, Research Show New Study Highlights the Impact of Early-Life Tobacco Exposure on Accelerated Aging See More AI in Biotech The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity How AI is Revolutionizing Antibiotic Discovery to Combat Drug-Resistant Bacteria Michigan-Based Biotech Startup CircNova Secures $3.3M Seed Funding to Advance AI-Driven Circular RNA Therapies Unlocking New Frontiers: How Generative AI is Transforming Protein Design and Drug Discovery See More Biotech Stocks Illumina’s Market Struggles Deepen as U.S.-China Tensions Escalate Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion Alumis IPO Priced at $16, Targets $210M Funding Diamond Biofund Becomes First Biotech VC Firm Listed on Taiwan Stock Exchange See More CRISPR A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030? Gene Editing for Everyone: CRISPRware and the Open-Source Biotech Revolution Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market See More Food Biotech Texas Ban on Lab-Grown Meat Triggers Policy and Legal Showdowns A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see The explainable aging clock regulators might actually like The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger See More Funding The patch that could unstick vaccination: Vaxxas’s A$90m bet on needle-free delivery From Platform to Precision: The $800M Bet Transforming Biotech Investing Draupnir Bio Raises €12 Million to Advance Oral Protein Degraders Targeting Extracellular Proteins Novo Holdings Leads $100 Million Series C Financing for Asceneuron German Biotech CatalYm Raises $150 Million for Phase 2b Cancer Studies See More Genomics From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care Epigenetic Stability Linked to Lifespan in Mammals, Research Show Orna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine Development AstraZeneca Completes Equity Investment in Cellectis to Enhance Gene Therapy Development Innovative Breakthrough in Genomics: Profluent’s OpenCRISPR-1 Revolutionizes Human Genome Editing See More Insights Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy Beijing’s Biotech Blitz Is Outpacing America. Washington Needs a War Plan. A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up See More Longevity A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong From Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging Breakthrough Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity The Billionaire Longevity Experiment: A Cruise Ship Promises to Extend Life—For a Price Manulife and World Economic Forum Launch Longevity Innovation Challenge See More M&A & Partnerships Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’? More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide Merck KGaA in Talks to Acquire U.S. Biotech Firm SpringWorks, Valued at $4 Billion Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion See More Neuroscience €132M for a Dutch Rare-Disease Upstart: Is Europe Quietly Becoming the New Neurology Capital? Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery Innovative Study on Addiction by Mount Sinai and Rockefeller University See More News The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger Galapagos quits cell therapy. Europe’s CGT reckoning begins. Dermatology’s next play: bispecifics that shut down OX40L and TNF From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal See More
Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy
Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity
Michigan-Based Biotech Startup CircNova Secures $3.3M Seed Funding to Advance AI-Driven Circular RNA Therapies
Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery
Michigan-Based Biotech Startup CircNova Secures $3.3M Seed Funding to Advance AI-Driven Circular RNA Therapies
Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy
Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity
Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery
